Risperidone in adolescent schizophrenic psychoses: A retrospective study

References

• Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry 2005; 66(Suppl 7)29–40
   PubMedGoogle Scholar
• Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53: 1090–7
   PubMed Web of Science ®Google Scholar
• Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. A open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994; 33: 658–63
   PubMed Web of Science ®Google Scholar
• Turetz M, Mozes T, Toren P, et al. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 1997; 170: 507–10
   PubMed Web of Science ®Google Scholar
• Kranzler H, Roofeh D, Gerbino-Rosen G, et al. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2005; 44: 55–63
   PubMed Web of Science ®Google Scholar
• Remschmidt H, Schultz E, Martin PDM. An open trial of clozapine in thirty six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 1994; 4: 31–41
   Web of Science ®Google Scholar
• Quintana H, Keshavan M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1995; 34: 1292–6
   PubMed Web of Science ®Google Scholar
• Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997; 36: 694–700
   PubMed Web of Science ®Google Scholar
• Hrdlicka M, Propper L, Vinar O, et al. Risperidone in the acute treatment of schizophrenia in adolescence [in Czech]. Cesk Slov Psychiat 1998; 94: 131–8
   Google Scholar
• Drtilkova I. Risperidone in children and adolescents with psychotic disorders of the schizophrenic type [in Czech]. Cesk Slov Psychiat 1999; 95(Suppl 2)22–29
   Google Scholar
• Zalsman G, Carmon E, Martin A, Bensason D, Weizman A, Tyano S. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 2003; 13: 319–27
   PubMed Web of Science ®Google Scholar
• Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996; 6: 251–7
   PubMed Web of Science ®Google Scholar
• Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37: 377–85
   PubMed Web of Science ®Google Scholar
• Sholevar EH, Baron DA, Hardie TL. Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 2000; 10: 69–78
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara N, Youngstrom EA, Branicky LA, Demeter CA, Schultz SC. A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2003; 42: 170–5
   PubMed Web of Science ®Google Scholar
• Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: open-label study. J Child Adolesc Psychopharmacol 2003; 13: 311–7
   PubMed Web of Science ®Google Scholar
• Ross RG, Novins D, Farley GK, Adler LE. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 2003; 13: 301–9
   PubMed Web of Science ®Google Scholar
• Maagensen M, Aarkrog T. Treatment of adolescent psychoses with olanzapine. Nord J Psychiatry 1999; 53: 435–8
   Web of Science ®Google Scholar
• Propper L, Hrdlicka M, Bares M. Olanzapine in the treatment of psychoses in adolescence [in Czech]. Cesk Slov Psychiat 2001; 97: 343–9
   Google Scholar
• Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001; 11: 415–24
   PubMed Web of Science ®Google Scholar
• McConville B, Carrero L, Sweitzer D, et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 2003; 13: 75–82
   PubMed Web of Science ®Google Scholar
• Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133–45
   PubMed Web of Science ®Google Scholar
• Gothelf D, Apter A, Reidman J, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 2003; 110: 545–60
   PubMed Web of Science ®Google Scholar
• Armenteros JL, Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry 2006; 15: 141–8
   PubMed Web of Science ®Google Scholar
• Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001; 62: 967–74
   PubMed Web of Science ®Google Scholar
• World Health Organization International classification of diseases. 10th ed. Geneva: WHO; 1992.
   Google Scholar
• National Institute of Mental Health Clinical Global Impression (CGI). Psychopharmacol Bull 1985;21:839–840.
   Google Scholar
• Kasper S, Rosillon D, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 179–87
   PubMed Web of Science ®Google Scholar
• Kasper S, Rosillon D, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 189–96
   PubMed Web of Science ®Google Scholar
• Aman MG, DeSmedt G, Derivan A, Lyons B, Findling RL and Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337–46.
   PubMed Web of Science ®Google Scholar
• Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41: 1026–36
   PubMed Web of Science ®Google Scholar
• Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006; 163: 402–10
   PubMed Web of Science ®Google Scholar
• , Research Unit on Pediatric Psychopharmacology Autism NetworkMcCracken JT, , et al. Risperidone in children with autism and serious behavioral problems. New Engl J Med 2002;347:314–21.
   PubMedGoogle Scholar
• Shea S, Turgay A, Caroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders. Pediatrics 2004; 114: 634–41
   PubMed Web of Science ®Google Scholar